The stock of TC Biopharm (Holdings) Plc (NASDAQ:TCBP) increased by $0.02 on Tuesday to at $0.58, up 3.78 percent. The last five days have seen an average of 266,912 shares of common stock traded. 3 times new highs were reached in the current year, with a fall of -$3.2499. The average number of shares traded over the last 20 days was 559,373, while the average volume over the last 50 days totaled 759,261.
TCBP stock dropped -6.45% since last month. On 08/22/23, the company’s shares reached a one-month low of $0.4394. The stock touched a high of $18.40 on 01/13/23, after rallying from a low of $0.42 in 52 weeks. The price of TCBP stock has declined by -84.94% or -$3.2499 this year, reaching a new high 3 times. Still, the stock price is down -96.85% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
TCBP stock investors should be aware that TC Biopharm (Holdings) Plc (TCBP) stock had its last reported insider trading activity 272 days ago on Nov 30. On Nov 30, 10% Owner Randall Diana Elizabeth acquired 70,000 shares at $5.00 each. This transaction resulted in the insider spending $350,000. On Nov 30, Randall Kenneth Edward added 70,000 shares at a price of US$5.00. After the transaction, the insider now owns 382,963 shares. 10% Owner Randall Mark Edward had earlier bought 70,000 shares on Nov 30 for $5.00 a share. The transaction was completed for $350,000.
Financial Health
For the recent quarter, TC Biopharm (Holdings) Plc’s quick ratio was 0.80, while its current ratio was 0.80, indicating its inability to pay off its debt. Based on annual data, it had gross profit of $19.65 million and revenue of $4.75 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. TCBP’s return on assets (ROA) during the last 12 months has been -14.00%. There was a -371.60% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 19.70%.
Earnings Surprise
Net income for the quarter came in at $3.84 million, while revenues rose by 48.44% to $0.0. At the end of TC Biopharm (Holdings) Plc’s most recent quarter, its liabilities totaled 13.58 million, while its total debt was $2.8 million.
Technical Picture
Here’s a quick look at TC Biopharm (Holdings) Plc’s (TCBP) price momentum from a technical perspective. As of 28 August, the RSI 9-day stood at 59.88%, suggesting the stock is Neutral, with a 76.89% historical volatility rate.
The stochastic %K and %D were 56.38% and 40.81% respectively, while the average true range (ATR) was 0.0831. Based on the 14-day stochastic reading of 80.11%, the RSI (14) reading is 54.92%. On the 9-day MACD Oscillator, the stock is at 0.0430, and the 14-day reading is at 0.0410.
Analyst Ratings
Analysts have assigned TC Biopharm (Holdings) Plc (TCBP) an Buy rating. TCBP is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 1 other recommend it as a buy.
What is TCBP’s price target for the next 12 months?
The current consensus forecast for the stock is between $5.61 and $5.61, with a median target price of $5.61. In analyzing these forecasts, the average price target given by analysts for TC Biopharm (Holdings) Plc (TCBP) is $5.61.
